<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563952</url>
  </required_header>
  <id_info>
    <org_study_id>1-2010-0023</org_study_id>
    <nct_id>NCT01563952</nct_id>
  </id_info>
  <brief_title>Impact of Intravascular Ultrasound(IVUS)-Guided Chronic Total Occlusion Intervention With Drug-eluting Stents</brief_title>
  <acronym>CTO</acronym>
  <official_title>Impact of IVUS-guided Chronic Total Occlusion InterVention With DrUg-eluting Stents on Mid-term Angiographic and Clinical Outcomes (CTO-IVUS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Guidance of stenting by IVUS has been proposed as a method to reduce restenosis rates,&#xD;
      because lumen and stent dimensions can be accurately determined by intravascular ultrasound&#xD;
      (IVUS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Guidance of stenting by IVUS has been proposed as a method to reduce restenosis rates,&#xD;
      because lumen and stent dimensions can be accurately determined by intravascular ultrasound&#xD;
      (IVUS). However, randomized studies investigating this strategy have yielded inconsistent&#xD;
      results. Therefore, the investigators hypothesized that the potential advantages of IVUS&#xD;
      guidance would be most apparent in Chronic Total Occlusion (CTO) intervention and try to&#xD;
      evaluate the impact of IVUS-guided chronic total occlusion intervention with drug-eluting&#xD;
      stents on mid-term angiographic, IVUS and clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event rate of cardiac death within 12 months</measure>
    <time_frame>12 months after CTO intervention.</time_frame>
    <description>Between IVUS guided intervention and non-IVUS guided intervention in patient with chronic total occlusion, the difference of post-procedural success rate, the combined event rate of cardiac death, MI and target lesion revascularization within 12 months. And incidence of composite events in cross over case of IVUS duing CTO intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE after stent implantation.</measure>
    <time_frame>24 months after CTO intervention</time_frame>
    <description>Incidence of cardiac death, MI, TLR and ST for 9, 12 and 24 months after stent implantation.&#xD;
Binary restenosis, late loss, restenosis %, restenosis type and follow-up MLD on follow-up angiography 1 year after CTO intervention&#xD;
Subgroup analysis; : Among the IVUS guided intervention group, Non-IVUS giuded intervention group and total patient group,&#xD;
To analyse difference of clinical outcome and angiographical outcome between Endeavor Resolute and Nobori stent.&#xD;
To analyse change of Stenting distal part using IVUS parameters.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Non-IVUS guided endeavor-R group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVUS guided endeavor-R group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-IVUS guided Nobori group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVUS guided Nobori group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)</intervention_name>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
    <arm_group_label>Non-IVUS guided endeavor-R group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)</intervention_name>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
    <arm_group_label>IVUS guided endeavor-R group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)</intervention_name>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
    <arm_group_label>Non-IVUS guided Nobori group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)</intervention_name>
    <description>2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.</description>
    <arm_group_label>IVUS guided Nobori group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥ 20 years or ≤ 80 years old&#xD;
&#xD;
          2. On coronary angiography, complete obstruction of coronary blood flow (TIMI grade 0)&#xD;
             with estimated occlusion duration ≥ 3months.&#xD;
&#xD;
          3. On coronary angiography, Reference vessel diameter of 2.5 to 4.0mm by operator&#xD;
             assessment&#xD;
&#xD;
          4. On coronary angiography, Total length of total occluded lesion and main lesion is less&#xD;
             than 80mm and lesions can be treated less than 4 stents.&#xD;
&#xD;
          5. Guide wire can be passed through occluded lesion without complications&#xD;
&#xD;
          6. Patients who can keep the dual antiplatelet treatment (aspirin, clopidogrel) more than&#xD;
             6 months after procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity reaction or side effects to Aspirin, Clopidogrel, Biolimus A9 and&#xD;
             Zotarolimus&#xD;
&#xD;
          2. unprotected Left main disease&#xD;
&#xD;
          3. Cardiogenic shock or LV ejection fraction ≤ 30%&#xD;
&#xD;
          4. Previous stent restenotic lesion&#xD;
&#xD;
          5. Treated within 2 weeks at the same lesion.&#xD;
&#xD;
          6. Creatinine level ≥ 2.0 mg/dL or ESRD&#xD;
&#xD;
          7. Severe tortuous and calcified lesion (Unobtainable IVUS image)&#xD;
&#xD;
          8. Life expectancy &lt; 1 year&#xD;
&#xD;
          9. Severe hepatic dysfunction (3 times normal reference values)&#xD;
&#xD;
         10. Pregnant women or women with potential childbearing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang-Soo Jang, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang-Soo Jang, MD.PhD.</last_name>
    <phone>+82 2 2228 8445</phone>
    <email>jangys1212@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jang, Yang-Soo</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu/Sinchon-dong</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang-Soo Jang, MD.PhD</last_name>
      <phone>+82 2 2228 8445</phone>
      <email>jangys1212@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Yang-Soo Jang, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Yangsoo Jang</investigator_full_name>
    <investigator_title>Professor of cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Umirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

